ArticleCancers2026
Inactivation of PRMT5 by PARP Inhibitors Confers High Susceptibility in MTAP-Deficient Cancers.
Qi Liu, Yuling Sheng, Folan Lin, Haoyuan Tan, Yanyun Chang, Xiaopeng Lu, Hao Chen, Changzheng Du
Abstract read
In one paragraphArticle in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
8 authors.
Qi LiuKey University Laboratory of Metabolism and Health of Guangdong, Biochemistry Department, School of Medicine, Southern University of Science and Technology, Shenzhen 518055, China.ORCID 0000-0001-5131-4446 Yuling ShengKey University Laboratory of Metabolism and Health of Guangdong, Biochemistry Department, School of Medicine, Southern University of Science and Technology, Shenzhen 518055, China.
Folan LinDepartment of Pharmacology, Joint Laboratory of Guangdong & Hong Kong Universities for Vascular Homeostasis and Diseases, SUSTech Homeostatic Medicine Institute, School of Medicine, Southern University of Science and Technology, Shenzhen 518055, China.
Haoyuan TanKey University Laboratory of Metabolism and Health of Guangdong, Biochemistry Department, School of Medicine, Southern University of Science and Technology, Shenzhen 518055, China.ORCID 0009-0002-8558-9717 Yanyun ChangCancer Center, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University, Beijing 102218, China.
Xiaopeng LuDepartment of Biochemistry and Molecular Biology, Shenzhen University Medical School, Shenzhen 518055, China.ORCID 0009-0002-6473-5826 Hao ChenDepartment of Human Cell Biology and Genetics, Joint Laboratory of Guangdong & Hong Kong Universities for Vascular Homeostasis and Diseases, School of Medicine, Shenzhen Key Laboratory of Gene Regulation and Systems Biology, Southern University of Science and Technology, Shenzhen 518055, China.
Changzheng DuCancer Center, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University, Beijing 102218, China.
Funding
National Natural Science Foundation of China 32170590
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
cancerMTAPPARPPRMT5therapy
Identifiers
PMID42122132
PMCPMC13163060
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390